Effects of amiodarone on cardiac function and mitochondrial oxidative phosphorylation during ischemia and reperfusion

被引:9
作者
Daniel Moreau
Fabienne Clauw
Lucie Martine
Alain Grynberg
Luc Rochette
Luc Demaison
机构
[1] INRA,Laboratoire de Physiopathologie et Pharmacologie Cardiovasculaires Expérimentales
[2] Unité de Nutrition Lipidique,undefined
[3] Université de Bourgogne,undefined
[4] Facultés de Médecine et de Pharmacie,undefined
[5] INRA,undefined
[6] Faculté de Pharmacie,undefined
来源
Molecular and Cellular Biochemistry | 1999年 / 194卷
关键词
amiodarone; arrhymias; mitochondrial oxidative phosphorylation; rat; heart;
D O I
暂无
中图分类号
学科分类号
摘要
This study was carried out in order to determine if the efficiency of amiodarone, a class III antiarrhythmic agent, is associated with changes in mitochondrial oxidative phosphorylation. A population of 30 rats were treated with amiodarone (100 mg/kg/day) for 5 days. A second population receiving only vehicle was used as control. The hearts were perfused according to the working mode. After 15 min of normoxic perfusion, the left main coronary artery was ligated and the ligation was maintained for 20 min. The ligation was removed and reperfusion continued for a further 30 min. The electrocardiogram was monitored continuously. At the end of perfusion, the ischemic and non ischemic areas were visually separated and mitochondria were harvested from each area. Their oxidative and energy metabolism were assessed with palmitoylcarnitine as substrate in 2 respiration media differing in their free calcium concentration (0 or 0.34 μm). In normoxic conditions, amiodarone treatment increased the cardiac metabolic efficiency (mechanical work to oxygen consumption ratio). The local ischemia decreased the aortic and coronary flows without modifying the cardiac metabolic efficiency. Amiodarone treatment maintained the aortic flow at a significantly higher value; the duration of severe arrhythmias was significantly decreased by the drug. The reperfusion of the ischemic area allowed the partial recovery of fluid dynamics. The coronary flow was restored to 89% of the pre ischemic value. Conversely, the aortic flow never exceeded that measured at the end of ischemia, partly due to the important development of severe arrhythmias. The recovery of aortic flow and metabolic efficiency during reperfusion was improved by amiodarone treatment; ventricular tachycardia and fibrillation duration were reduced. In the mitochondria issued from the normoxic area, the energy metabolism was not altered by the amiodarone treatment, but the presence of calcium in the respiration medium modified the oxidative phosphorylation. The divalent cation slightly decreased the state III respiration rate and increased noticeably the state IV respiration rate. This was associated with an important mitochondrial AMP production and maintenance of ADP in the respiration medium. This energy wasting was reported to decrease the mitochondrial metabolic efficiency. After an ischemia-reperfusion sequence, mitochondrial oxidation phosphorylation was reduced and amiodarone treatment amplified this decrease. This was presumably due to an increased mitochondrial calcium accumulation. Thus, the beneficial properties of amiodarone during reperfusion are supposed to be due to a protection against the deleterious effect of excess matrix calcium on mitochondrial energy metabolism.
引用
收藏
页码:291 / 300
页数:9
相关论文
共 150 条
[1]  
Charlier R(1968)Pharmacology of amiodarone, an antianginal drug with a new biological profile Arzneimittel-Forschung 18 1408-1417
[2]  
Deltour G(1984)Clinical pharmacokinetics of the newer antiarrhythmic agents Clin Pharmacokinetics 9 375-403
[3]  
Baudine A(1993)Oral amiodarone loading for the rapid treatment of frequent, refractory, sustained ventricular arrhythmias associated with coronary artery disease Am J Cardiol 72 395-399
[4]  
Chaillet F(1990)Antiarrhythmic effect of amiodarone on doxorubicin acute toxicity in working rat hearts Cardiovasc Res 24 653-658
[5]  
Gillis AM(1970)The effect of amiodarone, a new antianginal drug, on cardiac muscle Br J Pharmacol 39 57-67
[6]  
Kates RE(1983)Cardiac b-adrenoceptor modulation by amiodarone Biochem Pharmacol 32 473-477
[7]  
Russo AM(1987)The effects of amiodarone on serum thyroid hormones and hepatic thyroxine 5′-monodeiodination in rats Endocrinology 113 1464-1469
[8]  
Beauregard LA(1987)Amiodarone and the thyroid Clin Chem 35 1882-1887
[9]  
Waxman HL(1987)Amiodarone-induced lipidosis-like alterations in ocular tissues of rats Graef Arch Clin Exp 207 91-96
[10]  
Lambert C(1980)Ca Biochem Pharmacol 29 2969-2974